South Korea’s Ministry of the Interior and Safety (MOIS) has selected ‘health insurance coverage for hair loss treatments’ as the first agenda for its new public deliberation forum, signaling a potential policy shift that could reshape the domestic aesthetic and dermatology market. The move follows President Lee Jae-myung’s directive last December to review insurance coverage for hair loss care, a campaign pledge that has now entered formal public debate.
Policy context
MOIS announced on June 12 that it will operate a year-round public discussion platform called ‘Everyone’s Debate’ to address high-interest, life-related policy issues. The first on-site debate, scheduled for July 4 in Seoul, will focus on whether to include hair loss treatments under the National Health Insurance (NHI) scheme. The forum will feature expert presentations, in-depth participant discussions, and Q&A sessions aimed at generating policy alternatives.
Financial impact estimates
Government and parliamentary projections indicate that limiting coverage to androgenetic (M-shaped) alopecia in younger patients, with a 30–50% co-payment rate, would cost the NHI approximately 110–160 billion KRW (USD 85–123 million) annually. However, if coverage expands to include genetic and age-related hair loss, annual costs could surge to as high as 3 trillion KRW (USD 2.3 billion), raising concerns about fiscal sustainability.
Equity and priority debates
A key point of contention is the fairness of prioritizing hair loss treatment over severe or rare diseases. The Korean Medical Association has called for a comprehensive review of several health insurance expansion proposals, including hair loss, emergency room funding, and traditional Korean medicine for infertility. The debate will weigh the necessity of expanding coverage against the financial burden and competing healthcare priorities.
What buyers should watch
For overseas distributors and clinic buyers, the outcome of this debate could significantly affect demand for hair loss devices, injectables, and topical treatments in South Korea. If insurance coverage is approved, domestic clinics may increase procurement of FDA- or KFDA-approved hair restoration equipment and pharmaceuticals. Conversely, if coverage is limited or delayed, the private-pay market may continue to dominate. Importers should monitor the July 4 forum results and subsequent government decisions to adjust their supply-chain strategies for the Korean aesthetic market.
Source: Read the original report | Published: June 12, 2025